SOURCE: Spotlight Innovation Inc.

Spotlight Innovation Inc.

April 19, 2016 08:30 ET

Spotlight Innovation Achieves Key Laboratory Benchmark for Its Immunoplex Immunotherapy Cancer Vaccine Technology

WEST DES MOINES, IA--(Marketwired - Apr 19, 2016) - Spotlight Innovation Inc. (OTCQB: STLT) announced today that its proprietary Immunoplex™ epitope tag, which has previously been demonstrated to be stable, scalable, and producible in accordance with Good Manufacturing Practice (GMP), has now been demonstrated, in laboratory cell line models, to successfully attach to tumor cells in a consistent and reproducible manner. The epitope tag is used in conjunction with a universal antibody to create an immune complex vaccine to target a broad range of cancer and infectious disease indications.

Tony Vanden Bush, PhD, co-inventor of Immunoplex™ and Spotlight Innovation's Manager of Product Development, said, "We are gratified and excited to have demonstrated our ability to consistently label tumor cells with our epitope tag to enable antibody binding and immune system recognition of the labeled tumor cells. These results represent a significant benchmark in the development of our Immunoplex™ components, and are another key step in achieving a personalized treatment approach for cancer patients."

Cris Grunewald, President and Chief Executive Officer of Spotlight Innovation, said, "These recent laboratory results are clear confirmation of the viability of our proprietary epitope tag and constitute a significant milestone in the development of our immunotherapy platform technology. We are fully committed to advancing this immune complex cancer vaccine solution."

About Immunoplex™

Immunoplex™ is a vaccine platform technology that utilizes a "universal" antibody, in conjunction with a proprietary epitope "adapter," that binds to targeted antigens to treat or prevent specific diseases. Applications for the technology are solid cancerous tumors (a broad range of cancer indications) and a virtually unlimited number of viral and bacterial infections. This technology has the potential to create numerous "immune complex vaccines" for a wide range of indications. Because the Immunoplex™ therapy utilizes cancer cells from a patient's own tumor, it is a truly personalized cancer treatment.

About Spotlight Innovation Inc.

Spotlight Innovation Inc. (OTCQB: STLT) identifies and acquires rights to innovative and proprietary platform technology candidates with a focus on cancer drugs and related treatment therapies, solutions for infectious disease, and other specialty and unique opportunities. Access to platform technology candidates is accomplished via our extensive relationships with many leading academic institutions and other sources. We provide value-added development capability and funding in order to accelerate development progress. When commercially significant benchmarks have been achieved, we will partner with proven market leaders via sale, out-license or strategic alliance. For more information, visit or follow us on

Forward Looking Statements

Statements in this press release that are not purely historical are forward-looking statements. Forward-looking statements herein include statements regarding Spotlight Innovation's efforts to develop and commercialize Immunoplex™ and related technologies. Actual outcomes and actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the planned development of the technologies, the inability to hire appropriate staff to develop the technologies, unforeseen technical difficulties in developing the technologies, the inability to obtain regulatory approval for human use, competitors' therapies proving to be more effective, cheaper or otherwise more preferable, the inability to market a product, all of which could, among other things, delay or prevent product release, as well as other factors expressed from time to time in Spotlight Innovation's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Spotlight Innovation's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release and Spotlight Innovation undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Contact Information